Cme Group INC

CME Group announced strong financial results for Q2 2026, with record performance in the first half of the year driven by robust trading volumes and market data revenue.

CME Group Inc. is transitioning leadership as CEO Terry Duffy moves to Executive Chairman, with President and CFO Lynne Fitzpatrick succeeding him in March 2027.

CME Group reconvened its 2026 Annual Meeting to vote on proposals, with some failing to pass or achieve quorum, impacting director elections and charter amendments.

CME Group Inc. entered into Amendment No. 11 to its existing 364-day multi-currency revolving credit facility, maintaining a $7 billion capacity.

CME Group Inc. announced record-breaking financial results for the first quarter of 2026, driven by a 14% increase in revenue and a 22% rise in average daily volume across all asset classes.

CME Group Inc. reported record annual revenue, adjusted operating income, adjusted net income, and adjusted earnings per share for 2025, marking its fourth consecutive year of growth.

CME Group Inc. announced its financial results for the second quarter and first six months ended June 30, 2026, showing a slight increase in net income and revenue growth driven by market data services.

CME Group reported a 21% increase in net income for Q1 2026, driven by heightened market volatility and increased trading volumes across all asset classes.

CME Group reports a 3% decline in Q3 2025 total revenues but a 6% increase for the nine months, driven by higher investment income and market data growth despite lower trading volumes.

CME Group Inc. announced a significant increase in net income and revenues for the second quarter and first half of 2025, fueled by higher trading volumes across key product lines and robust investment income from performance bonds.

CME Group's Q1 2025 earnings surged, fueled by a significant increase in trading volumes across various product lines.

CME Group's Q3 2024 results show a significant increase in revenue and net income, driven by higher trading volumes across various product lines.

CME Group achieved significant financial growth in 2025, driven by record trading volumes and strategic advancements in cloud technology and new product offerings.

CME Group's 2024 annual report reveals record financial performance, fueled by increased trading volumes and market data demand, alongside strategic investments in technology and global expansion.

CME Group's 2023 annual report highlights record trading volumes and strategic growth initiatives, alongside regulatory and competitive challenges.

Robert J. Tierney Jr., a Director at CME Group Inc., received a grant of fully vested Class A Common Stock as part of the company's annual equity compensation program.

Martin J. Gepsman, a Director at CME Group Inc., received a grant of 645 fully vested shares of Class A Common Stock as part of the company's annual equity compensation program.

William R. Shepard, a Director at CME Group Inc., reported transactions involving the acquisition of common stock, including grants and dividend reinvestments.

Rahael Seifu, a Director at CME Group Inc., was granted fully vested Class A Common Stock as part of the company's annual equity compensation program.

Dennis Suskind, a Director at CME Group Inc., received a grant of fully vested Class A Common Stock as part of the company's annual equity compensation program.

Howard J. Siegel, a Director at CME Group Inc., reported transactions involving the acquisition of Class A Common Stock.

CME Group achieved its most successful year in 2025 with record revenue and trading volumes, while proposing significant corporate governance changes to eliminate Class B director election rights.

Several candidates are seeking election to the CME Group Board of Directors, outlining their qualifications, experience, and goals for the exchange's future.

CME Group Inc. will hold its annual shareholder meeting on May 8, 2025, where shareholders will vote on the election of directors, ratification of the independent auditor, and executive compensation.

CME Group achieved its best year in history in 2024, with record volume and revenue driven by increased demand for risk management tools amid global uncertainty.

Several candidates are vying for positions on the CME Group Board of Directors, outlining their qualifications and priorities in advance of the upcoming shareholder vote.

CME Group's 2024 Annual Meeting will be held on May 9, 2024, and shareholders are encouraged to vote on key proposals, including the election of directors and ratification of the company's auditor.

Vanguard Capital Management has reported a beneficial ownership of 27,044,709 shares, representing 7.45% of CME Group Inc.'s common stock as of March 31, 2026.

The Vanguard Group has amended its Schedule 13G filing for CME Group Inc., reporting zero beneficial ownership following an internal realignment.

The Vanguard Group filed an amendment to its Schedule 13G, disclosing a 10.1% beneficial ownership in CME Group Inc. common stock.